Grufity logoGrufity logo
StocksFundsScreenerSectorsWatchlists
ADMP

ADMP - Adamis Pharmaceuticals Corporation Stock Price, Fair Value and News

Delayed
Watchlist

ADMP Stock Price

View Fullscreen

ADMP RSI Chart

ADMP Valuation

Market Cap

8.0M

Price/Earnings (Trailing)

-0.36

Price/Sales (Trailing)

2.21

EV/EBITDA

-0.05

Price/Free Cashflow

-0.85

ADMP Price/Sales (Trailing)

ADMP Profitability

EBT Margin

-723.75%

Return on Equity

-6.99%

Return on Assets

-248.2%

Free Cashflow Yield

-117.33%

ADMP Fundamentals

ADMP Revenue

Revenue (TTM)

3.6M

Rev. Growth (Yr)

-99.4%

Rev. Growth (Qtr)

30.48%

ADMP Earnings

Earnings (TTM)

-22.2M

Earnings Growth (Yr)

68.45%

Earnings Growth (Qtr)

83.81%

Breaking Down ADMP Revenue

Last 7 days

-4.4%

Last 30 days

-44.7%

Last 90 days

-61.8%

Trailing 12 Months

137.5%

How does ADMP drawdown profile look like?

ADMP Financial Health

Current Ratio

0.58

ADMP Investor Care

Shares Dilution (1Y)

371.48%

Diluted EPS (TTM)

-9.56

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
20235.1M5.1M3.6M0
20222.9M3.5M4.2M4.9M
20216.9M4.2M4.1M2.2M
202021.9M20.0M15.0M10.1M
201916.8M18.7M20.7M22.1M
201813.2M13.3M13.8M15.1M
20178.1M9.8M11.4M13.1M
20160006.5M

Tracking the Latest Insider Buys and Sells of Adamis Pharmaceuticals Corporation

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
May 25, 2023
versi jannine
acquired
-
-
177,194
-
May 25, 2023
versi ebrahim
acquired
-
-
8,745
ceo
May 25, 2023
versi ebrahim
acquired
-
-
177,194
ceo
May 25, 2023
desai meera j.
acquired
-
-
3,138
-
May 25, 2022
carlo dennis j phd
acquired
-
-
250,000
-
Mar 18, 2022
benedicto david c.
sold
-2,207
0.6128
-3,603
chief financial officer
Mar 18, 2022
moss ronald b.
sold
-4,948
0.6036
-8,199
chief medical officer
Mar 18, 2022
marguglio david j.
sold
-7,116
0.6001
-11,859
svp and chief business officer
Mar 18, 2022
carlo dennis j phd
sold
-6,286
0.5993
-10,490
president & ceo
Dec 09, 2021
marguglio david j.
gifted
-
-
-13,000
svp of bus. dev & cbo

1–10 of 50

Which funds bought or sold ADMP recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
Feb 16, 2024
HARBOUR INVESTMENTS, INC.
unchanged
-
2.00
128
-%
Feb 14, 2024
HOLLENCREST CAPITAL MANAGEMENT
unchanged
-
1.00
20.00
-%
Feb 14, 2024
VANGUARD GROUP INC
added
12.96
3,071
23,803
-%
Feb 14, 2024
SUSQUEHANNA INTERNATIONAL GROUP, LLP
new
-
14,172
14,172
-%
Feb 14, 2024
TWO SIGMA SECURITIES, LLC
reduced
-39.21
-7,822
12,647
-%
Feb 14, 2024
BANK OF AMERICA CORP /DE/
unchanged
-
6.00
392
-%
Feb 14, 2024
GROUP ONE TRADING, L.P.
unchanged
-
1.00
66.00
-%
Feb 13, 2024
Tower Research Capital LLC (TRC)
added
171
29,077
45,642
-%
Feb 13, 2024
MORGAN STANLEY
reduced
-0.52
10.00
935
-%

1–10 of 30

Are Funds Buying or Selling ADMP?

Are funds buying ADMP calls or puts?
Calls
Puts
No. of funds holding Calls - Puts
Net Call Options
No. of funds that own ADMP
No. of Funds

Unveiling Adamis Pharmaceuticals Corporation's Major ShareHolders

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Feb 06, 2024
intracoastal capital, llc
6.0%
650,000
SC 13G/A
Sep 26, 2023
versi group llc
989%
1,018,024
SC 13D/A
Aug 10, 2023
intracoastal capital, llc
7.6%
650,000
SC 13G
Jun 05, 2023
versi group llc
9.99%
288,824
SC 13D
Feb 16, 2021
cvi investments, inc.
4.9%
4,918,972
SC 13G/A
Feb 28, 2020
cvi investments, inc.
7.9%
5,800,000
SC 13G
Feb 13, 2020
683 capital management, llc
2.8%
1,750,000
SC 13D/A
Feb 13, 2020
683 capital management, llc
2.8%
1,750,000
SC 13G/A
Feb 10, 2020
cvi investments, inc.
4.6%
3e+06
SC 13G/A
Feb 04, 2020
first manhattan co
0.00%
0
SC 13G/A

Recent SEC filings of Adamis Pharmaceuticals Corporation

View All Filings
Date Filed Form Type Document
Feb 07, 2024
8-K
Current Report
Feb 06, 2024
SC 13G/A
Major Ownership Report
Feb 05, 2024
8-K
Current Report
Jan 31, 2024
8-K
Current Report
Jan 23, 2024
DEFA14A
DEFA14A
Jan 23, 2024
8-K
Current Report
Jan 03, 2024
DEFA14A
DEFA14A
Jan 03, 2024
8-K
Current Report
Jan 03, 2024
8-K
Current Report
Dec 21, 2023
8-K
Current Report

Adamis Pharmaceuticals Corporation News

Latest updates
Yahoo Finance5 months ago
Pharmaceutical Technology Magazine8 months ago

Adamis Pharmaceuticals Corporation Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)
Income Statement (Quarterly)
Description(%) Q/Q2023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q42018Q3
Revenue30.5%9,0626,9451,453,0002,150,6821,505,68339,8471,154,514957,238759,9621,275,4741,393,097679,791868,0773,926,3424,663,2105,540,2235,902,9755,764,8994,905,7724,153,9073,832,935
Gross Profit7.1%-329,426-354,449-335,066-331,107-141,902-649,331-309,068-2,854,373-805,960-520,769-452,140-1,941,478-546,009-757,493976,1661,341,4031,914,0132,099,3341,280,3031,113,9081,532,503
  S&GA Expenses-37.6%2,517,1614,033,0834,782,0863,150,7882,508,1764,205,9343,382,6962,896,5584,794,4854,934,4913,518,0527,771,3353,308,6865,653,0926,054,3714,965,6575,300,1077,000,3398,021,4646,576,5716,534,745
  R&D Expenses---1,310,529859,8461,977,9393,320,6544,221,5252,195,7654,620,1432,196,7212,249,7441,349,3321,647,7463,085,8242,036,7322,014,9893,318,7432,845,7452,196,5147,800,7253,908,408
EBITDA Margin-43.2%-7.06-4.93-4.84-5.09-7.90-9.39-11.55-15.01-8.44-8.10-4.90-3.26-1.60-1.20-------
Interest Expenses-36.4%29,46546,312------1,8652,9001,884-33,1521,72232,92538,28754,36121,93522,95424,00825,01030,653
Income Taxes-----1,625--------8,900----1,045105---377,990-
Earnings Before Taxes----9,014,608-3,400,989-4,271,209--10,189,754-7,811,910-5,168,406---11,869,093-10,001,983--------
EBT Margin-41.3%-7.24-5.12-5.09-5.40-8.26-9.80-12.06-15.67-8.72-8.50-5.22-3.54-1.83-1.37-------
Net Income83.8%-1,388,046-8,574,122-8,942,907-3,327,536-4,398,901-8,397,221-10,354,615-8,774,186-12,361,048-9,313,730-15,379,234-17,858,809-11,361,198-12,924,713-7,246,369-3,890,126-6,999,751-7,735,587-8,887,305-12,810,757-8,875,283
Net Income Margin-24.5%-6.14-4.93-4.87-5.46-7.62-11.30-14.22-20.75-13.37-12.79-8.38-4.87-2.36-1.55-------
Free Cashflow-40.5%-3,737,240-2,660,028-1,639,032-1,613,537-7,705,834-10,248,888-7,012,664-6,900,825-9,915,818-17,249,854-4,942,249-5,381,080-5,929,796-5,526,706-------
Balance Sheet
(In Millions)
Balance Sheet
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q42018Q3
Assets88.6%9.005.009.0011.0012.0018.0031.0038.0045.0064.0081.0031.0044.0031.0045.0048.0053.0047.0053.0058.0070.00
  Current Assets128.1%8.003.008.009.0010.0015.0028.0035.0042.0046.0063.0013.0017.0012.0015.0014.0018.0012.0017.0026.0038.00
    Cash Equivalents940.8%7.001.003.001.002.009.0018.0023.0029.0040.0058.007.0012.008.0011.009.0012.004.009.0019.0032.00
  Inventory-0.2%1.001.001.001.001.000.000.000.00-2.003.001.002.002.003.002.003.003.003.003.003.00
  Net PPE-5.9%1.001.001.001.002.002.002.002.002.0010.0010.002.0011.0011.0011.0012.0012.0012.0011.0010.009.00
  Goodwill----------1.001.001.004.004.004.008.008.008.008.008.008.00
Liabilities-14.3%14.0016.0019.0012.009.0011.0015.0012.0011.0017.0025.0027.0023.0020.0014.0015.0013.0013.0013.0012.0012.00
  Current Liabilities-10.3%13.0015.0013.0011.009.0010.0014.0011.009.0013.0021.0020.0012.0012.0011.009.0011.0011.0011.0012.0012.00
Shareholder's Equity2.6%3183103043043.007.0016.0026.0034.0047.0055.006.0020.0020.0031.0033.0040.0034.0040.0047.0058.00
  Retained Earnings-0.4%-323-322-313-304-301-296-288-278-269-256-247-229-212-200-187-180-176-169-161-153-140
  Additional Paid-In Capital2.6%318310304304304304304304304304303233233221219214217203202200198
Shares Outstanding261.8%10.003.002.002.002.002.002.002.002.002.002.001.001.001.00-------
Float------74.00---163---39.00---61.00---
Cashflow (Last 12 Months)
(In Thousands)
Cashflow (Quarterly)
(In Thousands)
(*) denotes actual numbers (not divided by Thousands)
Description(%) Q/Q2023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q42018Q3
Cashflow From Operations-45.5%-3,737-2,568-1,547-1,522-7,498-9,894-6,985-6,673-9,766-16,808-4,536-5,411-6,109-5,140-4,239-2,938-4,257-4,416-8,273-12,275-7,981
  Share Based Compensation-185.6%-44.6952.0069.00-325-1574.003725491534.008809498298231,2192,2109.008821,9783,194-
Cashflow From Investing1178.0%1,7671388421557791,0171,5331,165-34.63-441-40618.00-53.91-636-274-301-361-538-1,665-364-1,900
Cashflow From Financing1061690.1%7,963750*2,724-----42.85-2,007-24.7956,011-12810,6493,1626,210-71.7312,648-143-141-12237,495

ADMP Income Statement

2023-06-30
UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)
3 Months Ended6 Months Ended
Jun. 30, 2023
Jun. 30, 2022
Jun. 30, 2023
Jun. 30, 2022
Income Statement [Abstract]    
REVENUE, net$ 6,945$ 39,847$ 1,459,945$ 1,194,361
COST OF GOODS SOLD361,394689,1782,149,4612,152,760
Gross Loss(354,449)(649,331)(689,516)(958,399)
SELLING, GENERAL AND ADMINISTRATIVE EXPENSES4,033,0834,205,9348,815,1687,588,630
RESEARCH AND DEVELOPMENT376,9573,320,6541,687,4867,542,179
ACQUIRED IN-PROCESS RESEARCH & DEVELOPMENT (IPR&D)6,539,6756,539,675
Loss from Operations(11,304,164)(8,175,919)(17,731,845)(16,089,208)
OTHER INCOME (EXPENSE)    
Interest Income70316,17471320,322
Interest Expense(46,312)(106,344)
Other Income/(Expense)463,018(257,832)410,017(697,832)
Gain/(Loss) on PPP2 loan62,583(1,787,417)
Excess of March 2023 Warrant Fair Value over Offering Proceeds(2,476,109)
Change in Fair Value of Warrants3,883,36419,5403,885,56928,927
Total Other Income (Expense), net4,300,773(159,535)1,713,846(2,436,000)
Net Loss from Continuing Operations(7,003,391)(8,335,454)(16,017,999)(18,525,208)
 DISCONTINUED OPERATIONS    
Net Loss from Discontinued Operations before Income Taxes(1,570,731)(61,767)(1,499,030)(226,628)
Income Taxes - Discontinued Operations
Net Loss from Discontinued Operations(1,570,731)(61,767)(1,499,030)(226,628)
Net Loss Applicable to Common Stock$ (8,574,122)$ (8,397,221)$ (17,517,029)$ (18,751,836)
Basic and Diluted Loss Per Share:    
Continuing Operations, Basic Loss Per Share[1]$ (2.79)$ (3.89)$ (6.81)$ (8.66)
Continuing Operations, Diluted Loss Per Share[1](2.79)(3.89)(6.81)(8.66)
Discontinued Operations, Basic Loss Per Share[1](0.61)(0.03)(0.63)(0.11)
Discontinued Operations, Diluted Loss Per Share[1](0.61)(0.03)(0.63)(0.11)
Basic Loss Per Share[1](3.40)(3.92)(7.44)(8.77)
Diluted Loss Per Share[1]$ (3.40)$ (3.92)$ (7.44)$ (8.77)
Basic Weighted Average Shares Outstanding[1]2,569,4002,140,2242,378,0062,138,816
Diluted Weighted Average Shares Outstanding[1]2,569,4002,140,2242,378,0062,138,816
[1]See Note 1, Reverse Stock Split 

ADMP Balance Sheet

2023-06-30
UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($)
Jun. 30, 2023
Dec. 31, 2022
CURRENT ASSETS  
Cash and Cash Equivalents (including $135,287 and $0 associated with variable interest entity at June 30, 2023 and December 31, 2022, respectively)$ 640,254$ 1,081,364
Restricted Cash30,09030,068
Accounts Receivable, net1,054,058
Receivable from Fagron18,97130,951
Inventories664,3581,238,778
Prepaid Expenses and Other Current Assets658,1191,884,015
Current Assets of Discontinued Operations1,438,9063,952,916
 Total Current Assets3,450,6989,272,150
LONG TERM ASSETS  
Fixed Assets, net1,142,8691,288,894
Right-of-Use Assets145,909317,622
Other Non-Current Assets9,67452,174
Total Assets4,749,15010,930,840
CURRENT LIABILITIES  
Accounts Payable11,365,9317,937,493
Deferred Revenue, current portion (including $147,118 and $0 associated with variable interest entity at June 30, 2023 and December 31, 2022, respectively)174,89727,779
Accrued Other Expenses2,200,7161,510,053
Product Recall Liability175,190305,806
Lease Liabilities, Current Portion157,246342,562
Current Liabilities of Discontinued Operations933,2461,272,173
Total Current Liabilities15,007,22611,395,866
LONG TERM LIABILITIES  
Deferred Revenue, net of current portion164,357178,247
Warrant Liabilities, at fair value1,072,8937,492
Total Liabilities16,244,47611,581,605
MEZZANINE EQUITY  
Convertible Preferred Stock - Par Value $0.0001; 10,000,000 Shares Authorized; Series C Preferred Stock 3,000 Shares Authorized, liquidation preference $110 per share; 3,000 Issued and Outstanding at June 30, 2023 and December 31, 2022, respectively330,000157,303
STOCKHOLDERS’ DEFICIT  
Convertible Preferred Stock - Par Value $0.0001; 10,000,000 Shares Authorized; Series E Preferred Stock 1,941.2 Shares Authorized, Issued and Outstanding at June 30, 2023 and no Shares Authorized, Issued and Outstanding at December 31, 2022
Common Stock - Par Value $0.0001; 200,000,000 Shares Authorized; 2,797,865  and 2,150,051 Issued, 2,790,395 and 2,142,581 Outstanding at June 30, 2023 and December 31, 2022, respectively[1]15,83115,051
Additional Paid-in Capital310,245,208303,746,217
Accumulated Deficit(322,081,115)(304,564,086)
Treasury Stock - 7,470 Shares, at cost[1](5,250)(5,250)
Total Stockholders’ Deficit(11,825,326)(808,068)
         Total Liabilities, Mezzanine Equity and Stockholders’ Deficit$ 4,749,150$ 10,930,840
[1]See Note 1, Reverse Stock Split

About Adamis Pharmaceuticals Corporation

ADMP

Adamis Pharmaceuticals Corporation Frequently Asked Questions


What is the ticker symbol for Adamis Pharmaceuticals Corporation? What does ADMP stand for in stocks?

ADMP is the stock ticker symbol of Adamis Pharmaceuticals Corporation. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Adamis Pharmaceuticals Corporation (ADMP)?

As of Tue Oct 31 2023, market cap of Adamis Pharmaceuticals Corporation is 7.99 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of ADMP stock?

You can check ADMP's fair value in chart for subscribers.

What is the fair value of ADMP stock?

You can check ADMP's fair value in chart for subscribers. The fair value of Adamis Pharmaceuticals Corporation is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Adamis Pharmaceuticals Corporation is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for ADMP so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Adamis Pharmaceuticals Corporation a good stock to buy?

The fair value guage provides a quick view whether ADMP is over valued or under valued. Whether Adamis Pharmaceuticals Corporation is cheap or expensive depends on the assumptions which impact Adamis Pharmaceuticals Corporation's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for ADMP.

What is Adamis Pharmaceuticals Corporation's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Tue Oct 31 2023, ADMP's PE ratio (Price to Earnings) is -0.36 and Price to Sales (PS) ratio is 2.21. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. ADMP PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Adamis Pharmaceuticals Corporation's stock?

In the past 10 years, Adamis Pharmaceuticals Corporation has provided -0.196 (multiply by 100 for percentage) rate of return.